EUVIMEDEUVIMED entdecken
Open Access

NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer

Junping Li, Hong Hu, Hui Lian, Shuo Yang, Manting Liu, Jinping He, Bihui Cao, Dongni Chen, Yuling Hu, Chen Zhi, Yan Shen, Xiaodie Ye und 8 weitere

International Journal of Biological Sciences · 2024 · 20 (5) · 1578-1601

DOI: 10.7150/ijbs.88539 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Biological Sciences, 2024. Verfasst von Junping Li und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology; Translational Medicine Center; Guangzhou Key Laboratory for Research and Development of Nano-Biomedical Technology for Diagn…. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Ovarian Neoplasms, Claudins. Die Arbeit wurde bisher 41-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The application of chimeric antigen receptor (CAR) NK cells in solid tumors is hindered by lack of tumor-specific targets and inefficient CAR-NK cell efficacy. Claudin-6 (CLDN6) has been reported to be overexpressed in ovarian cancer and may be an attractive target for CAR-NK cells immunotherapy. However, the feasibility of using anti-CLDN6 CAR-NK cells to treat ovarian cancer remains to be explored.

Methods

CLDN6 expression in primary human ovarian cancer, normal tissues and cell lines were detected by immunohistochemistry and western blot. Two types of third-generation CAR NK-92MI cells targeting CLDN6, CLDN6-CAR1 NK-92MI cells with domains containing self-activated elements (NKG2D, 2B4) and CLDN6-CAR2 NK-92MI cells with classical domains (CD28, 4-1BB) were constructed by lentivirus transfection, sorted by flow cytometry and verified by western blot and qPCR. OVCAR-3, SK-OV-3, A2780, Hey and PC-3 cells expressing the GFP and luciferase genes were transduced. Subcutaneous and intraperitoneal tumor models were established via NSG mice. The ability of CLDN6-CAR NK cells to kill CLDN6-positive ovarian cancer cells were evaluated in vitro and in vivo by live cell imaging and bioluminescence imaging.

Results

Both CLDN6-CAR1 and CLDN6-CAR2 NK-92MI cells could specifically killed CLDN6-positive ovarian cancer cells (OVCAR-3, SK-OV-3, A2780 and Hey), rather than CLDN6 negative cell (PC-3), in vitro. CLDN6-CAR1 NK-92MI cells with domains containing self-activated elements (NKG2D, 2B4) exhibited stronger cytotoxicity than CLDN6-CAR2 NK-92MI cells with classical domains (CD28, 4-1BB). Furthermore, CLDN6-CAR1 NK cells could effectively eliminate ovarian cancer cells in subcutaneous and intraperitoneal tumor models. More importantly, CAR-NK cells combined with immune checkpoint inhibitors, anti-PD-L1, could synergistically enhance the antitumor efficacy of CLDN6-targeted CAR-NK cells.

Conclusions

These results indicate that CLDN6-CAR NK cells possess strong antitumor activity and represent a promising immunotherapeutic modality for ovarian cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenOvarian NeoplasmsClaudinsHumansAnimalsMiceFemaleCell Line, TumorApoptosisNK Cell Lectin-Like Receptor Subfamily KCD28 AntigensKiller Cells, NaturalImmunotherapyImmunotherapy, Adoptive

Stichwörter der Autor:innen

Claudin-6NK cellsPD-1PD-L1chimeric antigen receptorovarian cancer

Substanzen

Receptors, Chimeric Antigenclaudin 6NK Cell Lectin-Like Receptor Subfamily KCD28 AntigensClaudins

Autor:innen und Institutionen

  • Department of Radiology; Translational Medicine Center; Guangzhou Key Laboratory for Research and Development of Nano-Biomedical Technology for Diagnosis and Therapy & Guangdong Provincial Education Department Key Labor…
  • Department of Radiology, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China.
  • Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and The Fifth Affiliat…
  • Department of Pathology, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
  • Minimally Invasive Interventional Division; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
  • Department of Interventional Therapy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510260, China.

Zitieren

APA

Li, J., Hu, H., Lian, H., Yang, S., Liu, M., He, J., Cao, B., Chen, D., Hu, Y., Zhi, C., Shen, Y., Ye, X., He, B., Zhao, M., Fan, W., Xu, L., Leidner, R., Wu, Q., Yang, L., & Zhang, Z. (2024). NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer. International Journal of Biological Sciences, 20(5), 1578-1601. https://doi.org/10.7150/ijbs.88539

Vancouver

Li J, Hu H, Lian H, Yang S, Liu M, He J, et al. NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer. International Journal of Biological Sciences. 2024;20(5):1578-1601. doi:10.7150/ijbs.88539

BibTeX
@article{Li2024,
  author = {Li, Junping and Hu, Hong and Lian, Hui and Yang, Shuo and Liu, Manting and He, Jinping and Cao, Bihui and Chen, Dongni and Hu, Yuling and Zhi, Chen and Shen, Yan and Ye, Xiaodie and He, Bingjia and Zhao, Ming and Fan, Weijun and Xu, Linfeng and Leidner, Rom and Wu, Qingde and Yang, Lili and Zhang, Zhenfeng},
  title = {NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer},
  journal = {International Journal of Biological Sciences},
  year = {2024},
  volume = {20},
  number = {5},
  pages = {1578--1601},
  doi = {10.7150/ijbs.88539}
}
Kostenlos starten →